ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

Rhea-AI Summary

ReShape Lifesciences (Nasdaq: RSLS) announced it will release its first-quarter financial results for 2022 on May 23, 2022, before the market opens. The company will also provide a corporate update during a webcast scheduled for 8:30 am ET on the same day. ReShape Lifesciences focuses on weight loss and metabolic health solutions, offering various FDA-approved and investigational products. Investors can access the results and the accompanying webcast link on the company’s website.

Positive

• Scheduled release of Q1 2022 financial results and corporate update, potentially enhancing transparency.
• Focus on comprehensive weight loss solutions, including FDA-approved products.

Negative

• None.

Webcast to be Held at 8:30 am ET on Monday, May 23, 2022

SAN CLEMENTE, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2022, including a corporate update, on Monday, May 23, 2022, pre-market.

Management will post a webcast at 8:30 am ET. A link to the webcast will be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.

An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.

About ReShape Lifesciences™

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. For more information, please visit www.reshapelifesciences.com.

CONTACTS:

Company Contact:                                        
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com                                       

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com 

FAQ

When will ReShape Lifesciences report its financial results for Q1 2022?

ReShape Lifesciences will report its Q1 2022 financial results on May 23, 2022, before the market opens.

What time is the ReShape Lifesciences webcast scheduled?

The webcast is scheduled for 8:30 am ET on May 23, 2022.

Where can I find the archived replay of the ReShape Lifesciences webcast?

The archived replay will be available in the 'Events and Presentations' section of ReShape's website.

What products does ReShape Lifesciences offer?

ReShape Lifesciences offers a range of weight loss and metabolic health solutions, including the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System.